« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | Actimid™ |
| Generic Name: | pomalidomide |
| Code Name: | CC-4047 |
| Company: | Celgene |
| FDA Clinical Phase: | I / II |
Description:
Actimid is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Actimid is a type of angiogenesis inhibitor and a type of immunomodulatory agent. Also called pomalidomide and CC-4047.
| Brand Name: |
Afinitor |
| Generic Name: |
everolimus |
| Code Name: |
RAD001 |
| Company: |
Novartis |
| FDA Clinical Phase: |
1/2 |
Description:
Afinitor was approved by the FDA in March 2009 for the treatment of advanced renal cell carcinoma, but it is currently also being studied in multiple myeloma.…
| Brand Name: | Aplidin® |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | II |
Description:
Aplidin is derived from a compound found in tunicates which shows promise in shrinking tumors. The specific marine organism is Aplidium albicans.
| Brand Name: | Atiprimod |
| Generic Name: | azaspirane |
| Code Name: | SK&F106615 |
| Company: | Callisto Pharmaceuticals |
| FDA Clinical Phase: | I / II |
Description:
A substance being studied in the treatment of certain multiple myelomas and other advanced cancers. Atiprimod may block the growth of tumors and the growth of new blood vessels that tumors need to grow. Atiprimod is a type of signal transduction inhibitor.
| Brand Name: | Avastin™ |
| Generic Name: | bevacizumab |
| Code Name: | rhuMAb-VEGF |
| Company: | Genentech Inc. |
| FDA Clinical Phase: | II |
Description:
Avastin is a monoclonal antibody used in the treatment of colorectal cancer that has spread. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may stop the growth of new blood vessels needed for tumors to grow. It is a type of antiangiogenesis agent.
| Brand Name: | Bexxar® |
| Generic Name: | iodine I 131 tositumomab |
| Code Name: | |
| Company: | GlaxoSmithKline |
| FDA Clinical Phase: | II |
Description:
Bexxar is a monoclonal antibody to which radioactive iodine 131 is attached, which targets a protein called CD20 found on the surface of a variety of B-cells, including lymphoma cells, and some myeloma cells. The radioactive iodine attached to the antibody delivers radiation directly to these cells which works to harm or kill the cancer cells. Approximately 20-25% of patients with multiple myeloma have this protein on the surface of their tumor cells.
